Saridaki Zenia

Dr. Zenia Saridaki-Zora is a Medical Oncologist, Director at the 1st Oncology Department at Metropolitan Hospital in Athens, Scientific Director at the Oncology Department, “Asklepios DIAGNOSIS,” and Collaborator at the Private Clinic “Asklepieion Crete,” in Heraklion, Crete. She graduated from the Medical School of the University of Crete, specialized in Medical Oncology, and completed post-graduate training at the University of Oxford and at Katholieke Universiteit Leuven (Belgium), where she served as a postdoctoral researcher at the Center for Human Genetics and the Department of Digestive Oncology.

She served as President of the Hellenic Society of Medical Oncology (ΗeSMO / ΕΟΠΕ) for two consecutive terms (2021–2023, 2023–2025), as the first woman in the Society’s history, and served as an elected member of the Board of Directors for six consecutive terms (2013–2025).

On December 20, 2022, she was appointed by the leadership of the Ministry of Health as Coordinator of the Working Group for the creation of the National Registry of Patients with Neoplastic Diseases, contributing decisively to the establishment of structures for oncology care in Greece. She also collaborated with the State, among others, to address the longstanding request of patients and physicians for updating the reimbursed list of biomarkers by EOPYY (October 2025), implementing a critical step for equal patient access to innovative therapies.

At the international level, she holds two key positions at ASCO (American Society of Clinical Oncology): she is Chair of the Central and Eastern Europe (CEE) Regional Council (re-elected on October 30, 2025) and a member of the ASCO Global Guidelines Advisory Group (GAG). She is also a member of the Advisory Board of the European Cancer Organisation (ECO) for the project #INTERACTEUROPE100, as well as a member of the European Society for Medical Oncology (ESMO). She is co-founder and member of the Steering Committee of Women for Oncology – W4O Hellas.

She has a substantial research and educational record with 57 publications in international scientific journals, more than 3,100 citations, an h-index of 27, and numerous scientific presentations and ePosters at international conferences including ESMO, ASCO, ESMO Breast Cancer, and ESMO Gastrointestinal Cancers. She has also been recognized by ASCO with a Certificate of Appreciation for her contribution to the international educational program ECHO Health After Cancer.

With extensive clinical, research, and educational experience, Dr. Zenia Saridaki is among the most recognized figures in contemporary Greek oncology, actively promoting scientific education, international collaboration, and the empowerment of women in the medical community.

Undergraduate Studies

• Medical School, University of Crete, Department of Health Sciences (1991–1997), Degree Grade: 8.01/10
• Three-month undergraduate clinical rotations through the ERASMUS program:
  • Pulmonology Clinic, Hôpital Civil de Strasbourg, Université Louis-Pasteur, Faculté de Médecine de Strasbourg, France (1994)
  • Pediatrics Clinic, Hôpital Universitaire des Enfants “Reine Fabiola”, Université Libre de Bruxelles, Faculté de Médecine, Belgium (1996)

Postgraduate Studies

• PhD, Medical School, University of Crete (1997–2002)
  • Thesis: “Genetic analysis of microsatellite DNA sequences in cutaneous neoplastic lesions”
  • Supervisor: Prof. D.A. Spandidos
  • Grade: Excellent

Specialty

• Medical Oncology Specialty, University Hospital of Heraklion (PaGNI), Crete (1999–2007)
  • Includes 6 months in Hematology
  • Radiation Oncology training, Radiation Oncology Clinic, PaGNI (12/2006-01/2007)
  • Medical Oncology Specialty Certification (24/09/2007)

Postgraduate / Postdoctoral Training

• Academic visitor at Oxford University, Medical Oncology Unit of Churchill and John Radcliffe Hospitals, and Department of Clinical Pharmacology, Radcliffe Infirmary, under Prof. David J. Kerr (Feb–June 2007)
• European Certification in Medical Oncology (ESMO Examination) (Sept 2007–2012)
• Full-time postdoctoral researcher at Center for Human Genetics O&N1, Katholieke Universiteit Leuven, and Department of Digestive Oncology, University Hospital Gasthuisberg Leuven, Belgium (01/12/2010–30/11/2011). Supervisor: Prof. Sabine Tejpar
• ΗeSMO Research Fellowship for postdoctoral employment abroad (2010–2011)
• Scientific collaborator, University Medical Oncology Clinic, PaGNI, and postdoctoral researcher, Cancer Biology Laboratory, Medical School, University of Crete (2012–2014)

Languages

• English (Excellent)
• French (Excellent)

2012: Honorary Scientific Collaborator, Department of Medical Oncology, University Hospital of Heraklion, Crete (PaGNi), participated in oncology research programs; Postdoctoral researcher, Laboratory of Cancer Biology, Medical School, University of Crete (until 2014)

2010: HeSMO Research Fellowship, 1-year postdoctoral research abroad (Protocol 2936/17-02-2011)

2010: Full-time postdoctoral research fellow, Center for Human Genetics O&N1, Katholieke Universiteit Leuven & Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium (1/12/2010 – 30/11/2011), supervisor: Prof. Sabine Tejpar

2007: Collaborating clinical researcher, Clinical Studies Unit, Department of Medical Oncology, PaGNi; Postdoctoral researcher, Laboratory of Cancer Biology, Medical School, University of Crete

2007: European Certification in Medical Oncology (ESMO Examination)

2007: Specialization in Medical Oncology (24/9/2007)

2007: Academic visitor, Oxford University, Medical Oncology Unit, Churchill & John Radcliffe Hospitals, and Department of Clinical Pharmacology, Radcliffe Infirmary; supervisor: Prof. David J. Kerr

2006: Radiotherapy training, Medical Oncology specialty, PaGNi (1/12/2006–31/1/2007)

2003: Specialization in Medical Oncology, PaGNI, including 6 months Hematology

2002: Assistant Researcher, Clinical Studies Unit, Department of Medical Oncology, PaGNI (Nov 5, 2002 – Sep 14, 2003)

2002: PhD, “Genetic analysis of microsatellite DNA sequences in cutaneous neoplastic lesions,” Medical School, University of Crete, Grade: Excellent (6/11/2002)

2002: Completion of the first three years of Internal Medicine residency, including 6 months in Hematology, for the specialization in Medical Oncology at PaGNI (Nov 4, 2002)

2001: Visiting researcher, Genomic Instability Group, Roy Castle International Center for Lung Cancer Research, Liverpool, UK (20/10/2001–16/11/2001)

1999: Commencement of the first three years of Internal Medicine residency, including 6 months in Hematology, for the specialization in Medical Oncology at PaGNI

1997: Start of rural medical service (duration 1 year)

1997: Approval of the commencement of the PhD research by the Medical School of the University of Crete (18/12/1997), supervisor Prof. D.A. Spantidos

1997: MD, University of Crete, Grade 8.01/10, 6-year program

1996: Undergraduate clinical Erasmus exchange, Pediatrics, Hôpital Universitaire des Enfants “Reine Fabiola”, Université Libre de Bruxelles, Belgium

1994: Undergraduate clinical Erasmus exchange, Pulmonology, Hôpital Civil de Strasbourg, Université Louis Pasteur, France

1991: Admission to Medical School, University of Crete (numerous clausus, national exams)

1990: Greek High School Diploma, Grade 19.5/20

• President of the Hellenic Society of Medical Oncology (ΗeSMO) for two consecutive terms (2021–2023, 2023–2025), first woman and youngest person in this position in the Society’s history; elected Board member for six consecutive terms (2013–2025) and member since 2008
• Member of the Hellenic Cooperative Oncology Group (HeCOG) since 2017, co-coordinator of the GI group
• Member of the Central and Eastern Europe (CEE) Regional Council, ASCO since 2023; Head since 2025 (re-elected 30/10/2025); member of the ASCO Global Guidelines Advisory Group (GAG) since 2024
• Member of the European Society for Medical Oncology (ESMO) since 2003; represented Greece in the ESMO National Societies Committee (2022–2025)
• Member of the Advisory Board of the European Cancer Organisation (ECO) for the project #INTERACTEUROPE100 (from July 2024)
• Co-founder and member of the Steering Committee of W4O Hellas – Women in Oncology since 2014

Long-standing participation in medical education and lifelong learning in oncology.

• Lecturer, coordinator, and invited faculty in numerous CME programs, workshops, and seminars organized by ΗeSMO, ESMO, and ASCO
• Since January 2025, recognized with the Certificate of Appreciation by ASCO and its International Education Steering Group for her contribution to the fight against cancer, as Planning Committee and Faculty member in the international educational program ASCO- HESMO Health After Cancer ECHO Program: Greece, implemented for the first time in Greece between November 2024 and April 2025
• During her presidency, ΗeSMO, inaugurated the 2023 Memorandum of Cooperation with the Hellenic Open University (HOU) for the Hellenic Oncology Academy (EAKO) — the Society’s key educational initiative was upgraded to a Short Postgraduate Program of HOU (leading to a Certificate of Specialized Education) integrated into its Program for Lifelong Learning

Director at the 1st Oncology Department at the Metropolitan Hospital, Neo Faliro, Athens (2022–Present)

• Responsible for monitoring, diagnosing, and treating oncology patients in collaboration with the Department’s staff in an environment which supports the full spectrum of Medical Oncology including targeted therapies, immunotherapies, classic and innovative chemotherapies, best supportive care, and genetic counseling
• Principal Investigator (PI) and Sub-Investigator (SI) in clinical trials, providing patients access to cutting-edge treatments

Scientific Director, Oncology Department, “Asklepios DIAGNOSIS,” Heraklion, Crete (2012–Present)

• Responsible for the diagnosis, treatment, and follow-up of oncology patients, in interdisciplinary collaboration
• Development of personalized therapeutic protocols and introduction of innovative monitoring practices for every patient

Collaborator, Private Clinic “Asklepieion Crete,” Heraklion, Crete (2012–Present)

• Provides specialized oncology services, emphasizing interdisciplinary approaches and continuous update of therapeutic practices as per national and international protocols

2025: Past President of the Board of Directors, Hellenic Society of Medical Oncology (HeSMO) (1st Term: 2021-2023, 2nd Term: 2023-2025)

2024: Honorary Scientific Collaborator at the Committee for the Control of the Electronic Pre-Approval System (EPCS) of the National Organization for Health Care Services Provision (EOPYY), appointed April 2024 by the Minister of Health, Mr. Adonis Georgiadis

2023: Re-elected to the HeSMO Board of Directors (April 2023 – 6th term) and 2nd term as President of the Board (2023-2025)

2022: Coordinator of the Working Group for the creation of the National Registry of Patients with Neoplastic Diseases (appointed 20/12/2022 by the Minister of Health Mr. Athanasios Plevris)

2022: Director at the 1st Oncology Clinic, Metropolitan Hospital, Athens

2021: Re-elected to the HeSMO Board (April 2021 – 5th term) and 1st election as President (2021-2023); the first woman and the youngest person in HeSMO history

2019: Re-elected to HeSMO Board (April 2019 – 4th term) and first election as Vice-President

2017: Re-elected to HeSMO Board (April 2017 – 3rd term) and elected as Secretary

2015: Re-elected to HeSMO Board (April 2015 – 2nd term) and elected General Secretary

2014: Deputy Managing Editor, official English-language journal of HeSMO, Forum of Clinical Oncology (FCO) (2014–2017)

2013: Elected Member of HeSMO Board (April 2013 – 1st term), elected Special Secretary

Since 2012: Scientific Head, Oncology Department “Asklepios DIAGNOSIS”

Since 2012: Consultant, Private Clinic “Asklepieion of Crete”, Heraklion

• Volunteer Scientific Collaborator, University Medical Oncology Clinic, PaGNI (2012–2014): participation in clinical and laboratory research and resident education
• Postdoctoral Researcher, Cancer Biology Laboratory, University of Crete, Medical School (2007–2010): participation in clinical and laboratory studies in Medical Oncology
• Full-time Postdoctoral Scientific Researcher, Center for Human Genetics O&N1 & Department of Digestive Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium (2010–2011): translational research on gene expression and molecular characteristics of gastrointestinal neoplasms under Prof. Sabine Tejpar

• Clinical and translational research in colorectal, breast, gastric, pancreatic, and lung cancers
• Research on predictive and prognostic biomarkers in solid tumors
• Study of resistance mechanisms to targeted therapies and immunotherapies
• Integration of molecular and genetic features in personalized therapeutic approaches
• Member of HeCOG clinical and translational research team since 2017, co-coordinator of the GI group
• Participation in research projects and phase I–III clinical trials at University of Crete, University Hospital Gasthuisberg (Leuven, Belgium), and international collaborations
• Postdoctoral research at Center for Human Genetics & Department of Digestive Oncology, Katholieke Universiteit Leuven, Belgium, under Prof. Sabine Tejpar: gene expression and molecular characteristics of gastrointestinal tumors
• Collaborating researcher, Cancer Biology Laboratory, University of Crete: molecular pathogenesis of neoplastic diseases
• ΗeSMO Research Fellowship recipient for postdoctoral work abroad

• Certificate of Appreciation, ASCO & International Education Steering Group (2025) for her contribution to the fight against cancer as Planning Committee and Faculty member for the ASCO-HESMO Health After Cancer ECHO Program in Greece
• Postdoctoral Research Fellowship, Center for Human Genetics O&N1 & Department of Digestive Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium, funded by ΗeSMO (2010–2011)

• Author or co-author of 57 articles in peer-reviewed journals (3,171 citations; h-index 27; i10-index 43; total impact factor 843.8) and numerous scientific presentations and ePosters at international conferences (ESMO, ASCO, ESMO Breast Cancer, ESMO Gastrointestinal Cancers)
• Research focuses on breast, lung, gastrointestinal cancers, immunotherapy, biomarker-driven prognosis, and personalized oncology
• Deputy Managing Editor, ΗeSMO’s official English-language journal, Forum of Clinical Oncology (FCO) (2014–2017)

Scientific Publications

Empowering Primary Care Providers (PCPs) in Cancer Survivorship: Insights from the ASCO | HeSMO Project ECHO in Greece. Tsoukalas N., Razis E., Boukovinas I., Lionis C., Chatzifoti N., Eaton V., Gould A., Kremzier M., Sarchet V., Schapira L., Saridaki Z. (2025). Presentation No. 3192eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. (Abstract accepted; to be published in Annals of Oncology Supplement.)

The landscape of PIK3CA mutations and their prognostic impact on recurrence in HR+/HER2- breast cancer: A real-world multicenter analysis. Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025.Boutis A., Nikolaou M., Ardavanis A., Zagouri F., Koumarianou A., Timotheadou E., Tolis C., Christopoulou A., Korantzis I., Kampletsas E., Liontos M., Loga K., Kesisis G., Biziota I., Papatsimpas G., Karageorgopoulou S., Antoniadou K., Chatzifoti N., Saridaki Z. (2025).Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. (Abstract accepted; to be published in Annals of Oncology Supplement.)

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrri, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A

Vagionas, P Papakostas, A Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology, 5, 1073, https://doi.org/10.1016/j.esmogo.2024.100073

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study, E Fountzilas, S Karageorgopoulou, G Karakatsoulis, D Tryfonopoulos, K Papazisis, A Koutras, A Koumarianou, G Zafeiri, E Biziota, A Nikolaidi, I Boukovinas, E Vrana, D Mauri, E Aravantinou-Fatorou, E Razis, E Vorrias, Z Saridaki, D Bafaloukos, A Christopoulou, A Boutis, N Tsoukalas, S Stamatopoulou, N Spathas, M Theochari, F Zagouri, A Psyrri, G Fountzilas, E Lalla,

Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report, Zacharenia Saridaki, Elena Fountzilas, Athanasios Alexopoulos, Niki Karachaliou, BMC Medical Genomics

Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece, S Manolakou, N Tsoukalas, E Saloustros, T Makatsoris, I Boukovinas, A Christopoulou, A Karampeazis, I Bompolaki, I-I Varthalitis, E Voulgaris, K Ballasis, A Boutis, E Galani, C Kalofonos, A Koumarianou, C Kourousis, P Papakotoulas, C Papandreou, E-I Perdikouri, A Andreadou, I Athanasiadis, F-I Dimitrakopoulos, C Emmanouilidis, E Kampletsas, O Katopodi, P Kosmidis, K Koutsoukos, E Lianos, P Makrantonakis, E Ntouvelis, C Panopoulos, V Papadopoulos, G Pentheroudakis, E Samantas, I Stoupis, G Tsironis, N Chatzifoti, I Souglakos, Z Saridaki, ESMO Gastrointestinal Oncology, 8, 100153, https://doi.org/10.1016/j.esmogo.2025.100153

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrri, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A Vagionas, P Papakostas, A Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology 5, 100073

Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, Journal of Clinical Oncology 42 (16_suppl), 3146-3146

Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer., Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilas, Natalia Chatzifoti, Zacharenia Saridaki, Journal of Clinical Oncology 42 (16_suppl), e23139-e23139

Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial., Ting Pu, Allyson Peddle, Pratyaksha Wirapati, Yourae Hong, Leslie Samuel, Jayesh Desai, Maigo Riener, Zacharenia Saridaki, David Cunningham, Sabine Tejpar, Petros Tsantoulis, Journal of Clinical Oncology 42 (16_suppl), 3592-3592

Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns, Elena Fountzilas, Theofanis Papadopoulos, Eirini Papadopoulou, Cedric Gouedard, Helen P Kourea, Pantelis Constantoulakis, Christina Magkou, Maria Sfakianaki, Vassiliki Kotoula, Dimitra Bantouna, Georgia Raptou, Angelica A Saetta, Georgia Christopoulou, Dimitris Hatzibougias, Electra Michalopoulou-Manoloutsiou, Eleni Siatra, Eleftherios Eleftheriadis, Evangelia Kavoura, Loukas Kaklamanis, Antigoni Sourla, George Papaxoinis, Kitty Pavlakis, Prodromos Hytiroglou, Christina Vourlakou, Petroula Arapantoni-Dadioti, Samuel Murray, George Nasioulas, Grigorios Timologos, George Fountzilas, Zacharenia Saridaki, Diagnostics 14 (11), 1076

Complete response as prognostic marker of prolonged survival in metastatic melanoma, D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, EJC Skin Cancer 2

Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer., Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilas, Natalia Chatzifoti, Zacharenia Saridaki Journal of Clinical Oncology Volume 42, Number 16_suppl https://doi.org/10.1200/JCO.2024.42.16_suppl.e23139

Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., Emmanouil S Saloustros, Michael Liontos, Eleni Timotheadou, Charalampos Andreadis, Efthymia Skafida, John Syrios, Antonia Kalykaki, Konstantinos Koutsoukos, Georgios Kesisis, Ioannis Boukovinas, Anastasios L Boutis, Pavlos Papakotoulas, Dimitrios C Ziogas, Sofia Karageorgopoulou, Stylianos Giassas, Evangelos Lianos, Natalia Chatzifoti, Fotini Papageorgiou, Zacharenia Saridaki, Journal of Clinical Oncology Volume 42, Number 16_suppl https://doi.org/10.1200/JCO.2024.42.16_suppl.3146

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer, Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsaousis, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, Florentia Fostira, George Fountzilas, Michalis Liontos, Cancers 15(23), 5525

Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). , Michael Liontos, Eleni Timotheadou, Emmanouil S Saloustros, Anna Koumarianou, Ilias Athanasiadis, Sofia Karageorgopoulou, Pavlos Papakotoulas, Ioannis Syrios, Georgios Kesisis, Christos Papadimitriou, Eirini Biziota, Maria Skondra, Stylianos Giassas, Eleftherios Kampletsas, Stavros Peroukidis, Christos Christodoulou, Fotini Papageorgiou, Ioannis Boukovinas, Zacharenia Saridaki, Journal of Clinical Oncology 40 (16_suppl), e18520-e18520

Abstract P5-13-01: Comprehensive tumor analysis by NGS in metastatic breast cancer patients, Eirini Papadopoulou, Nikolaos Tsoulos, Vasiliki Metaxa-Mariatou, Aikaterini Tsantikidi, Georgios Kapetsis, Chrysiida Florou-Chatzigiannidou, Sonia Maravelaki, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Tsaousis, Nikolaos Touroutoglou, Dimitrios Trafalis, Ioannis Boukovinas, Ioannis Varthalitis, Zacharenia Saridaki, Charalampos Zoublios, Eleni Galani, George Papatsibas, Christos Papadimitriou, Tania Zlatintsi, Polixenia Iorga, Bülent Orhan, Sualp Tansan, Tahsin Özatlı, George Nasioulas, Cancer Research 82 (4_Supplement), P5-13-01-P5-13-01

Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVer study): a prospective cohort study of the Hellenic Cooperative Oncology Group, Helena Linardou, Nikolaos Spanakis, Georgia-Angeliki Koliou, Athina Christopoulou, Sofia Karageorgopoulou, Nephely Alevra, Anastasios Vagionas, Nikolaos Tsoukalas, Stavroula Sgourou, Elena Fountzilas, Joseph Sgouros, Evangelia Razis, Dimitra Chatzokou, Sofia Lampaki, Zacharenia Saridaki, Giannis Mountzios, George Saroglou, George Fountzilas, Cancers 13 (18), 4621

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254

Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma, Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrri, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou, Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas, Philippos C Patsalis, Cancers 13 (2), 198

Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, ESMO open 6 (6), 100306

P75. 04 advanced lung cancer inflammation index (ALI), neutrophil-to-lymphocyte ratio (NLR), and PD-(L) 1 inhibitor efficacy in NSCLC, G Mountzios, E Samantas, K Senghas, E Zervas, J Krisam, K Samitas, F Bozorgmehr, J Kuon, S Agelaki, S Baka, I Athanasiadis, L Gaissmaier, M Elshiaty, L Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, K Kriegsmann, P Kosmidis, R El Shafie, M Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C Heussel, F Herth, H Winter, C Emmanouilidis, G Oikonomopoulos, M Meister, T Muley, H Bischoff, Z Saridaki, E Razis, E Perdikouri, A Stenzinger, I Boukovinas, M Reck, K Syrigos, M Thomas, P Christopoulos, Journal of Thoracic Oncology 16 (3), S573-S574

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group,Elena Fountzilas, Georgia-Angeliki Koliou, Athanassios Vozikis, Vassiliki Rapti, Achilleas Nikolakopoulos, Anastasios Boutis, Athina Christopoulou, Ioannis Kontogiorgos, Sofia Karageorgopoulou, Efthalia Lalla, Dimitrios Tryfonopoulos, Ioannis Boukovinas, Cleopatra Rapti, Adamantia Nikolaidi, Sofia Karteri, Evangelia Moirogiorgou, Ioannis Binas, Davide Mauri, Gerasimos Aravantinos, Flora Zagouri, Zacharenia Saridaki, Amanda Psyrri, Dimitrios Bafaloukos, Anna Koumarianou, Helena Linardou, Giannis Mountzios, Evangelia Razis, George Fountzilas, Georgios Koumakis, ESMO open 5 (4), e000774

Association of notch and hedgehog pathway activation with prognosis in early-stage colorectal cancer, Grigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, Kyriaki Manousou, Georgia-Angeliki Koliou, Ioannis Kostopoulos, Vassiliki Kotoula, Thomas Makatsoris, Helen P Kourea, Georgia Raptou, Sofia Chrisafi, Epaminontas Samantas, Kleo Papaparaskeva, Elissavet Pazarli, Pavlos Papakostas, Georgia Kafiri, Davide Mauri, Alexandra Papoudou-Bai, Christos Christodoulou, Kalliopi Petraki, Nikolaos Dombros, Dimitrios Pectasides, George Fountzilas, Anticancer Research 39 (4), 2129-2138

PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer, M Sfakianaki, C Papadaki, M Tzardi, M Trypaki, S Manolakou, I Messaritakis, Z Saridaki, D Mavroudis, V Georgoulias, J Souglakos, Annals of Oncology 30, iv21-iv22

334P - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting, E Fountzilas, G-A Koliou, V Rapti, A Nikolakopoulos, A Christopoulou, E Moirogiorgou, I Binas, G Aravantinos, L Kostadima, A Nikolaidi, S Karteri, F Zagouri, Z Saridaki, A Molfeta, P Oikonomopoulou, D Tryfonopoulos, G Koumakis, G Fountzilas, E Razis, Annals of Oncology 30, v118

Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Zacharenia Saridaki, Emmanouil S Saloustros, Nikolaos Tsoukalas, Thomas Makatsoris, Georgios Lypas, Haralabos Kalofonos, Athina Christopoulou, Iliada Bompolaki, Ioannis Sougklakos, Evangelos Voulgaris, Athanasios Karampeazis, Christos Papandreou, Athanasios Anagnostopoulos, Eleni P Galani, Konstantinos Ballasis, Flora Zagouri, Georgios Rizos, Athanasios Athanasiadis, Ioannis I Varthalitis, Ioannis Boukovinas, Journal of Clinical Oncology 37 (15_suppl), e13141-e13141

Colchicum genus in the writings of ancient Greek and Byzantine physicians, Gregory Tsoucalas, Theodoros Papaioannou, George Panayiotakopoulos, Zenia Saridaki, Dimitrios A Vrachatis, Marianna Karamanou, Current pharmaceutical design 24 (6), 648-653

One in four women with high-grade serous ovarian cancer carries a loss-of-function BRCA1 & BRCA2 germline allele, F Fostira, MS Papamentzelopoulou, E Saloustros, P Apostolou, V Mollaki, A Vagena, K Tsakiri, I Athanasiadis, E Timotheadou, G Lypas, Z Saridaki, I Boukovinas, G Aravantinos, M Liontos, C Papadimitriou, I Varthalitis, D Yannoukakos, A Athanasiadis, I Konstantopoulou, EUROPEAN JOURNAL OF HUMAN GENETICS 26, 530-531

Hellenic Alliance for Metastatic Breast Cancer: A Platform of Support, a Platform for Life, A Tarampikou, Z Saridaki, S Kolokotroni, A Christopoulou, S Agelaki, E Galani, A Psyrri, A Nikolaidi, H Linardou, Journal of Global Oncology, 165s-165s

Access to Genetic Testing Impacts Oncologists ́ Decisions on Ovarian Cancer Personalized Treatment: Lessons Learned From a National Program in Greece, I Boukovinas, G Lypas, M Liontos, C Andreadis, C Papandreou, P Papakotoulas, G Aravantinos, E Bournakis, S Karageorgopoulou, E Maragkouli, N Ziras, S Kakolyris, I Athanasiadis, E Linardou, A Koumarianou, C Kalofonos, G Pentheroudakis, I Korantzis, C Christodoulou, P Kosmidis, D Daliani, A Ardavanis, G Koumakis, I Bankousli, P Makrantonakis, G Kesisis, M Nikolaou, E Diamantidou, N Tsoukalas, I Xanthakis, A Fassas, V Barbounis, A Anagnostopoulos, A Polyzos, A Athanasiadis, I Syrios, S Peroukidis, I Mpompolaki, S Baka, N Androulakis, V Georgoulias, C Emmanouilidis, D Mavroudis, I Sgouros, C Stathopoulos, O Katopodi, I Varthalitis, P Sarikaki, E Saloustros, Z Saridaki, Journal of Global Oncology, 74s-74s

Frequent germline BRCA1/2 mutations in women with ovarian cancer and the need for insurance coverage of genetic testing: A Hellenic Society of Medical Oncology (HeSMO) national program. , Georgios Lypas, Zacharenia Saridaki, Emmanouil S Saloustros, Michael Liontos, Evangelos Bournakis, Christos Papandreou, Evangelos Lianos, Haralabos Kalofonos, Elena Maragouli, Gerasimos Aravantinos, Nikolaos Xenidis, Charalampos Andreadis, Eleni Stergiou, Alexandros Bokas, Cedric Gouedard, George Nasioulas, Fotini Papageorgiou, Athanasios Athanasiadis, Ioannis Varthalitis, Ioannis Boukovinas, Journal of Clinical Oncology 36 (15_suppl), e13525-e13525

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity, Pratyaksha Wirapati, Valentina Pomella, Ben Vandenbosch, Peter Kerr, Evaristo Maiello, Mark Jeffery Grahame, Razvan-Ovidiu D Curca, Meinolf Karthaus, John A Bridgewater, Anca C Mihailov, Igor Kiss, Sandra Merino, James McKendrick Joseph, Zacharenia Saridaki, Xavier JA Sagaert, Sabine Tejpar, Annals of Oncology 28, iii151-iii152

Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy, S Pontikakis, C Papadaki, M Tzardi, M Trypaki, M Sfakianaki, F Koinis, E Lagoudaki, L Giannikaki, A Kalykaki, E Kontopodis, Z Saridaki, N Malamos, V Georgoulias, J Souglakos, The pharmacogenomics journal 17 (6), 506-514

André Levret (1703-1780): the eminent obstetrician of the 18th century and his innovative approach to the treatment of uterine polyps, Marianna Karamanou, Christos Iavazzo, Zenia Saridaki, Konstantinos Gritzalis, George Androutsos, Balkan Union of Oncology. Journal 22, 562-565

New treatments in Oncology: Clinical practice regarding the management of Adverse Events (AEs). Results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO), M Liontos, F Koinis, G Chatsidis, K Kamposioras, G Papaxoinis, M Nikolaou, K Tsigaridas, E Voulgaris, E Pantavou, G Aravantinos, A Ardavanis, I Boukovinas, E Galani, S Angelaki, G Mountzios, Z Saridaki, I Varthalitis, N Tsoukalas, Annals of Oncology 28, v517

Reduced expression of SMAD4 is associated with poor survival in colon cancer, Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas Alexander McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fredrik T Bosman, Roberto Fiocca, Clinical Cancer Research 22 (12), 3037-3047

P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG), John Souglakos, Zacharenia Saridaki, N Gouges, Alexandra Voutsina, Maria Tzardi, Aristea Kalikaki, Maria Sfakianaki, Athanasios Athanasiadis, Evangelos Xynos, Ioannis Boukovinas, Annals of Oncology 27, ii9

Career Development and Oncology Education in Europe: Final results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)., Nikolaos Tsoukalas, Eleni Aravantinou-Fatorou, Konstantinos Kamposioras, Athanasios Korogiannos, Vasileios Papadopoulos, Ioannis Kostakis, George Lazaridis, Michail Nikolaou, Evangelos Voulgaris, Michael Liontos, Kostas Tsigaridas, Evangelos Bournakis, Athanasios Athanasiadis, Gerasimos Aravantinos, Alexandros Ardavanis, Ioannis Boukovinas, Eleni P Galani, Giannis Mountzios, Zacharenia Saridaki, Ioannis Varthalitis, Journal of Clinical Oncology 34 (15_suppl), e18202-e18202

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, D Klingbiel, Z Saridaki, AD Roth, FT Bosman, M Delorenzi, Sabine Tejpar, Annals of oncology 26(1), 126-132

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?, Z Saridaki, X Saegart, Veerle De Vriendt, D Hatzidaki, Sander Palmans, Linde De Smedt, Gert De Hertogh, Sabine Tejpar, British Journal of Cancer 113 (6), 914-920

René-Théophile-Hyacinthe Laennec (1781-1826) and the description of metastatic pulmonary melanoma, M Karamanou, AJ Stratigos, Z Saridaki, G Tsoucalas, G Androutsos, J BUON 20 (1), 354-6

Avenzoar’s (1091-1162) clinical description of cancer, M Karamanou, G Tsoucalas, Z Saridaki, C Iavazzo, G Androutsos, J BUON 20 (4), 1171-4

How to identify the right patients for the right treatment in metastatic colorectal cancer (mCRC), Z Saridaki, N Asimakopoulou, I Boukovinas, J Souglakos, Current Colorectal Cancer Reports 11, 151-159

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma, Zacharenia Saridaki, Georgia Lambrodimou, Stefanos Kachris, Paris Makrantonakis, Ioannis Boukovinas, Aris Polyzos, Athanasios Anagnostopoulos, Athanasios Athanasiadis, Dimitris Stoltidis, Vassilis Georgoulias, John Souglakos, American Journal of Clinical Oncology 38 (1), 17-22

Prognostic and predictive significance of MSI in stages II/III colon cancer, Z Saridaki, J Souglakos, V Georgoulias, Z Saridaki, J Souglakos, V Georgoulias, World Journal of Gastroenterology: WJG 20 (22), 6809

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy, Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar, Clinical Cancer Research 20 (17), 4499-4510

ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samplesExpressão ERCC1 Correlacionada com EGFR e VariáRevista Portuguesa de Pneumologia (English Edition) 20 (4), 200-207veis Clinicopatológicas em Doentes com

Carcinoma Pulmonar de Não Pequenas Células. Um estudo imunocitoquímico em amostras biópsias aspirativas por agulha fina, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, Z Saridaki, M Tzardi, Revista Portuguesa de Pneumologia (English Edition) 20(4), 200-207

Cost-effectiveness analysis of panitumumab+ mFOLFOX over bevacizumab+ mFOLFOX as a first-line treatment for metastatic colorectal cancer patients with wild-type RAS in Greece, G Kourlaba, I Boukovinas, Z Saridaki, V Papagiannopoulou, G Tritaki, N Maniadakis, Value in Health 17 (7), A633

Women 4 Oncology in Greece: Exploring Common Challenges-Survey of the Hellenic Society of Medical Oncology Among Women Oncology Professionals, H Linardou, A Christopoulou, S Agelaki, E Galani, Z Saridaki, A Psyrri, A Athanasiadis, Annals of Oncology 25, v1

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Its Impact on Patients’ Outcome, Zacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, Chara Papadaki, Alexandra Voutsina, Aristea Kalykaki, Ippokratis Messaritakis, Kyriakos Mpananis, Dimitris Mavroudis, Efstathios Stathopoulos, Vassilis Georgoulias, John Souglakos, PloS one 8 (12), e84604

The eminent dermatologist Moriz Kaposi (1837-1902) and the first description of idiopathic multiple pigmented sarcoma of the skin, M Karamanou, C Antoniou, AJ Stratigos, Z Saridaki, G Androutsos, J buon 18 (4), 1101-5

Genetic alterations in colorectal cancer in older patients, Z Saridaki, J Souglakos, Management of Colorectal Cancers in Older People, Management of Colorectal Cancers in Older People, 2013, p. 9-20

A retrospective analysis regarding the parameters, which influence the administration of adjuvant chemotherapy in for elderly patients (>70years) with stage II or III colon cancer in the daily clinical practice, N Asimakopoulou, P Papakonstantinou, J Souglakos, A Karampeazis, Z Saridaki, P Koinis, A Matikas, C Nikolaou, V Georgoulias, L Vamvakas, Journal of geriatric oncology 4, S40-S41

Pkm2 Expression Could Predict Resistance to Oxaliplatin Combination Chemotherapy in Patients with Stage Ii/Iii or Metastatic Colorectal Cancer, G Mountzios, E Samantas, K Senghas, E Zervas, J Krisam, K Samitas, F Bozorgmehr, J Kuon, S Agelaki, S Baka, I Athanasiadis, L Gaissmaier, M Elshiaty, L Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, K Kriegsmann, P Kosmidis, R El Shafie, M Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C Heussel, F Herth, H Winter, C Emmanouilidis, G Oikonomopoulos, M Meister, T Muley, H Bischoff, Z Saridaki, E Razis, E Perdikouri, A Stenzinger, I Boukovinas, M Reck, K Syrigos, M Thomas, P Christopoulos, Annals of Oncology 24, iv115

Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer, Z Saridaki, J Souglakos,Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance, Springer New York

The great surgeon Jean-Louis Faure (1863-1944) and his contribution in the treatment of uterine cancer, M Karamanou, Z Saridaki, M Piagkou, K Laios, G Androutsos, J BUON 18 (1), 296-298

Aretaeus of Cappadocia and the first description of diabetes, K Laios, M Karamanou, Z Saridaki, G Androutsos, Hormones 11, 109-113

Clinical implications and quality assurance of molecular testing for EGFR-targeting agents in colorectal cancer, Loredana Vecchione, Zenia Saridaki, Sabine Tejpar, Current Colorectal Cancer Reports 8, 42-50

Gastrointestinal tumors, colorectal, D Arnold, HJ Schmoll, J Riera-Knorrenschild, F Mayer, H Kroening, W Scheithauer, D Nitsche, M Tschaika, M Schmidt, B Wittig, T Price, K Wilson, RJ Simes, D Yip, CS Karapetis, NC Tebbutt, V Gebski, M Fournier, DR Ferry, D Ransom, R Salazar, E Mini, G Folprecht, F Subtil, J van Laethem, J Thaler, JA Bridgewater, E Van Cutsem, C Lepage, J Taieb, S Venderbosch, T De Haan, DAM Heideman, TS Maughan, CG Smith, P Quirke, SD Richman, ID Nagtegaal, CJA Punt, M Koopman, T Bachleitner-Hofmann, I Simon, R Salazar, J Tabernero, R Rosenberg, J van der Akker, Y Li, B Chan, G Lanza, A Glas, MJ O'Connell, M Lee, M Lopatin, G Yothers, KM Clark-Langone, C Millward, S Paik, S Sharif, S Shak, N Wolmark, P Li, G Chen, P Laurent-Puig, G Manceau, J Bachet, B Chibaudel, F Liebaert, O Bouché, F Penault-Llorca, MD Diebold, T André, S Imbeaud, V Heinemann, R Laubender, DP Modest, A Jung, L Fischer von Weikersthal, U Vehling-Kaiser, C Giessen, T Kirchner, U Mansmann, S Stintzing, A Custodio, J Moreno, J Aparicio, J Gallego Plazas, C Fernández Martos, J Maurel, D Ramos, P Cejas, R Madero, J Feliu, AAL Pereira, JFM Rego, PM Hoff, A Sasse, RP Riechelmann, E Mitry, L Venat-Bouvet, J Phelip, E Maillard, J Jouve, X Adhoute, D Gargot, M Gasmi, L Bedenne, T Aparicio, RS Midgley, S Love, V Potter, E Segelov, DR Ferry, A Weaver, C Scudder, P Julier, S Grumett, DJ Kerr, S Ahmed, RK Shahid, A Leis, K Haider, P Pahwa, T Price, J Hardingham, C Lee, A Townsend, J Wrin, K Wilson, A Weickhardt, RJ Simes, C Munroe, N Tebbutt, IB Tan, T Seah, SL Koo, S Choo, CK Tham, D Chong, I López Calderero, AC Moya, AA Gonzalez, AC Carranza, MC Conde, S Molina-Pinelo, MDP Herrera, MLL Miron, PE Garcia, R Garcia- Carbonero, F Cappuzzo, A Sacconi, Annals of Oncology-English Edition 23 (9), ix178

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (MCRC) In Daily Clinical Practice: Correlations with Clinical Characteristics, Prognostic and Predictive Values, Z Saridaki, M Tzardi, M Sfakianaki, C Papadaki, K Mpananis, E Tsakalaki, M Trypaki, I Messaritakis, V Georgoulias, J Souglakos, Annals of Oncology 23, ix213

PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines., C Papadaki, Z Saridaki, M Tzardi, M Sfakianaki, G Sfakiotaki, M Trypaki, I Messaritakis, D Mavroudis, V Georgoulias, I Sougklakos, Journal of Clinical Oncology 30 (4_suppl), 468-468

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients, Zacharenia Saridaki, BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome, Z Saridaki, D Papadatos-Pastos, M Tzardi, D Mavroudis, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulias, J Souglakos, British journal of cancer 102 (12), 1762-1768

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer, Zacharenia Saridaki, Vassilis Georgoulias, John Souglakos, World journal of gastroenterology: WJG 16 (10), 1177

A retrospective analysis of non-platinum-based first-and second-line chemotherapy in patients with advanced non-small cell lung cancer, Athanasios Kotsakis, Dora Hatzidaki, Lambros Vamvakas, Nikolaos Vardakis, Antonia Kalykaki, Vasiliki Bozionelou, Nikolaos Androulakis, Kostas Kalbakis, Zacharenia Saridaki, Vassilis Georgoulias, Sophia Agelaki, Anticancer research 30 (10), 4335-4342

Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study., ES Saloustros, K Kalbakis, NK Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulias, D Mavroudis, Journal of Clinical Oncology 28 (15_suppl), 1133-1133

PAZOPANIB: a second generation antiangiogenic multitargeted tyrosine kinase inhibitor, N Karaxaliou, Z Saridaki, ForuM of CliniCAl onColoGY, 33-39

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, JA Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, CS Fuchs, MH Kulke, RA Shivdasani, British journal of cancer 101 (3), 465-472

Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study, Charalambos Kouroussis, Lambros Vamvakas, Nikolaos Vardakis, Athanasios Kotsakis, Antonia Kalykaki, Kostas Kalbakis, Zacharenia Saridaki, Nikolaos Kentepozidis, Stelios Giassas, Vassilis Georgoulias, Oncology 76 (2), 112-117

A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors, Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Marios Marselos, Vassilis Georgoulias, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 65, 121-128

1016 Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy, Z Saridaki, M Tzardi, D Papadatos-Patsos, E Kampouraki, E Zois, E Stathopoulos, V Georgoulias, D Mavroudis, J Souglakos, EJC Supplements 2 (7), 91-92

Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial, Ioannis Gioulbasanis, Zacharenia Saridaki, Antonia Kalykaki, Lambros Vamvakas, Kostas Kalbakis, Michail Ignatiadis, Kyriakos Amarantidis, Stylianos Kakolyris, Vassilis Georgoulias, Dimitris Mavroudis, Anticancer research 28 (5B), 3019-3025

The relationship between measures of nutritional status and Comprehensive Geriatric Assessment, Z Giannousi, L Vamvakas, E Saloustros, A Karampeazis, I Gioulbasanis, G Sfakiotaki, E Kontopodis, Z Saridaki, V Bozionelou, V Georgoulias, Critical Reviews in Oncology/Hematology, S33

A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors, A Kalykaki, L Vamvakas, Sofia Agelaki, K Kalbakis, N Vardakis, G Sfakiotaki, Michail Ignatiadis, Z Saridaki, A Karampeazis, D Mavroudis, V Georgoulias, Oncology 71 (3-4), 197-203

A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors, Zacharenia Saridaki, Vasiliki Bozionelou, Nikolaos Kentepozidis, Athanasios Kotsakis, Nikolaos Vardakis, Antonia Kalykaki, Ioannis Gioulbasanis, Athanasios Karampeazis, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis, Oncology 72 (1-2), 45-50

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract, I Gkioulbasanis, J Souglakos, N Vardakis, A Kotsakis, Z Saridaki, N Kentepozidis, A Polyzos, S Giassas, Michail Ignatiadis, V Bozionelou, C Christophylakis, Vassilis Georgoulias, JOURNAL-BALKAN UNION OF ONCOLOGY 12 (2), 197

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status, John Souglakos, Lambros Vamvakas, Stella Apostolaki, Maria Perraki, Zacharenia Saridaki, Irine Kazakou, Athanasios Pallis, Charalambos Kouroussis, Nikos Androulakis, Kostas Kalbakis, Georgia Millaki, Dimitris Mavroudis, Vassilis Georgoulias, Breast Cancer Research 8 (4), 1-8

Correlation of microsatellite instability (MSI) status with clinical parameters and treatment outcomes for patients with metastatic colorectal cancer (MCC) treated with a triplet combination with irinotecan (CPT-11), oxaliplatin (L-OHP) plus bolus and infusional 5FU/leucovorin (degramont regimen)-FOLFOXIRI, I Souglakos, D Papadatos-Pastos, M Tzardi, Z Saridaki, N Zois, M Peraki, D Mavroudis, V Georgoulias, ANNALS OF ONCOLOGY 17, 44-44

Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors, Ch Kouroussis, N Androulakis, L Vamvakas, A Kalykaki, S Spiridonakou, N Kentepozidis, Z Saridaki, El Xiropoulou, V Georgoulias, Oncology 69 (3), 202-207

Idiopathic CD4+ T lymphocytopenia disclosed by recurrent cryptococcal meningitis. First case report from Greece, Diamantis P Kofteridis, Zacharenia Saridaki, Ireni Kazakou, Silvia Lazaridou, Dimitris Alegakis, Georgia Milaki, Achilleas Gikas, International Journal of Infectious Diseases 9 (6), 347-348

A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors, John Souglakos, Stylianos Kakolyris, Nikolaos Vardakis, Nikolaos Androulakis, Dimitrios Mavroudis, Lambos Vamvakas, Charalambos Kouroussis, Sophia Agelaki, Zacharenia Saridaki, Vassilis Georgoulias, Cancer investigation 23 (6), 505-510

Endothelial p21WAF1/Cip1 cell cycle inhibitor is down-regulated in breast cancer, T Vrekoussis, EN Stathopoulos, M Kafousi, Z Saridaki, E Sanidas, O Zoras, Anticancer research 25 (4), 2743-2748

First line chemotherapy with docetaxel plus gemcitabine in elderly or poor performance status patients with advanced non-small cell lung cancer: the experience of the Hellenic Oncology Research Group (HORG)." M Ignatiadis, K Kalbakis, N Vardakis, S Giassas, G Sfakiotaki, Z Saridaki, V Bozionelou, J Gioulbasakis, A Pallis, V Georgoulias, EJC SUPPLEMENTS 3 (2), 332-332

First line treatment with docetaxel and cisplatin in non-small cell lung cancer patients: A retrospective analysis, N Kentepozidis, S Agelaki, L Vamvakas, A Kotsakis, Z Saridaki, J Gioulbasakis, A Kalykaki, M Ignatiadis, G Sfakiotaki, D Mavroudis, LUNG CANCER 49, S251-S251

Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine, J Souglakos, N Androulakis, A Kalykaki, Z Saridaki, N Vardakis, K Kalbakis, S Agelaki, L Vamvakas, N Kentepozidis, S Giassas, D Mavroudis, V Georgoulias, ANNALS OF ONCOLOGY 16, 41-41

P-509 First line treatment with docetaxel and cisplatin in non-small celllung cancer patients: A retrospective analysis, N Kentepozidis, S Agelaki, L Vamvakas, A Kotsakis, Z Saridaki, J Gioulbasakis, A Kalykaki, M Ignatiadis, G Sfakiotaki, D Mavroudis, Lung Cancer, S250-S251

Intestinal ischemia as the first manifestation of vasculitis, Freda H Passam, Ioannis D Diamantis, Garyfalia Perisinaki, Zenia Saridaki, Herakles Kritikos, Dimitrios Georgopoulos, Dimitrios T Boumpas, Seminars in arthritis and rheumatism 34 (1), 431-441

A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC), D Mavroudis, E Efstathiou, A Polyzos, A Athanasiadis, G Milaki, E Kastritis, A Kalykaki, Z Saridaki, A Dimopoulos, V Georgoulias, Journal of Clinical Oncology 22 (14_suppl), 5020-5020

Increase incedence of central nervous system (CNS) involvement for patients with breast cancer (BC) treated with Taxanes based chemotheraoy, J Souglakos, L Vamvakas, Z Saridaki, I Kazakou, A Pallis, K Kalbakis, A Kalikaki, V Biozionelou, V Georgoulias, ANNALS OF ONCOLOGY 15, 30-30

A non-comparative study of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with cisplatin-sensitive and-refractory advanced ovarian cancer, D Mavroudis, E Efstathiou, G Aravantinos, M Karina, A Polyzos, E Kastritis, A Kalikaki, Z Saridaki, MA Dimopoulos, V Georgoulias, ANNALS OF ONCOLOGY 15, 130-130

Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, O Zoras, DA Spandidos, British Journal of Dermatology 148 (4), 638-648

First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer, G Fiorentini, D Tsetis, P Bernardeschi, C Varveris, S Rossi, A Kalogeraki, E Athanasakis, P Dentico, P Kanellos, M Biancalani, S Almarashdah, G Zacharioudakis, Z Saridaki, G Chalkiadakis, E Xynos, O Zoras, Anticancer research 23 (5), 4339-4346

Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction, DP Kofteridis, S Karabekios, JG Panagiotides, J Bizakis, D Kyrmizakis, Z Saridaki, A Gikas, Journal of chemotherapy 15 (3), 282-286

Paclitaxel, carboplatin and gefitinib ('Iressa', ZD1839) as first-line chemotherapy in patients with advanced breast cancer: a phase II study, G Founizilas, D Pectasides, DV Skarlos, H Kalofonos, C Papadimitriou, H Linardou, A Kalogera-Fountzila, Z Saridaki, E Briassoulis, S Papadopoulos, S Lambropoulos, P Kosmidis, E Razis, H Gogas, BREAST CANCER RESEARCH AND TREATMENT 82, S85-S85 / Conference: 26th Annual San Antonio Breast Cancer Symposium

Mutations of p16INK4a and p14ARF tumor suppressor genes in SCC of the skin and lack of mutation in BCC, UJ Zoras, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, DA Spandidos, ANNALS OF SURGICAL ONCOLOGY 10 (1), S78-S79

Surgical repair of incisional ventral hernias: tension-free technique using prosthetic materials (expanded polytetrafluoroethylene Gore-Tex Dual Mesh), Emmanuel Chrysos, Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Dimitra Dimitriadou, Vasilios Koutsoumpas, George Chalkiadakis, Evangelos Xynos, Odysseas Zoras, The American Surgeon 66 (7), 679-682

High frequency of loss of heterozygosity on chromosome region 9p21–p22 but lack of p16INK4a/p19ARF mutations in Greek patients with basal cell carcinoma of the skin, Zacharenia Saridaki, George Sourvinos, Demetrios A Spandidos, Elma Koumantaki, Triantafillos Liloglou, Othon Papadopoulos, Odysseas Zoras, Journal of investigative dermatology 115 (4), 719-725

Surgical repair of inguinal hernia: tension free technique with prosthetic materials (Gore- Tex Mycro Mesh expanded polytetrafluoroethylene), Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Emmanuel Chrysos, George Prokopakis, Nickolaos Vrahasotakis, Evangelos Xynos, George Chalkiadakis, Odysseas Zoras, The American Surgeon 66 (8), 728-731

Publications, Presentations, and ePosters produced by ΗeSMO under her Presidency (2021–2025)

Articles in International Peer-Reviewed Journals with Impact Factor:

Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid tumors. Journal of Chemotherapy, Pappas G., Tsoukalas N., Boutis A., Saloustros E., Gazouli I., Gkoura S., Zakopoulou R., Aidarinis C., Boukovinas I., Koumarianou A., Kokkali S., Gkoumas G., Vlachostergios P.J., Assi A., Karampeazis A., Nikolaidi A., Fountzilas E., Chatzifoti N., Saridaki Z. (2025) under review (2nd round).

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study, E Fountzilas, S Karageorgopoulou, G Karakatsoulis, D Tryfonopoulos, K Papazisis, A Koutras, A Koumarianou, G Zafeiri, E Biziota, A Nikolaidi, I Boukovinas, E Vrana, D Mauri, E Aravantinou-Fatorou, E Razis, E Vorrias, Z Saridaki, D Bafaloukos, A Christopoulou, A Boutis, N Tsoukalas, S Stamatopoulou, N Spathas, M Theochari, F Zagouri, A Psyrri, G Fountzilas, E Lalla, ESMO Real World Data and Digital Oncology, 7, 1095, https://doi.org/10.1016/j.esmorw.2024.100095

Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece, S Manolakou, N Tsoukalas, E Saloustros, T Makatsoris, I Boukovinas, A Christopoulou, A Karampeazis, I Bompolaki, I-I Varthalitis, E Voulgaris, K Ballasis, A Boutis, E Galani, C Kalofonos, A Koumarianou, C Kourousis, P Papakotoulas, C Papandreou, E-I Perdikouri, A Andreadou, I Athanasiadis, F-I Dimitrakopoulos, C Emmanouilidis, E Kampletsas, O Katopodi, P Kosmidis, K Koutsoukos, E Lianos, P Makrantonakis, E Ntouvelis, C Panopoulos, V Papadopoulos, G Pentheroudakis, E Samantas, I Stoupis, G Tsironis, N Chatzifoti, I Souglakos, Z Saridaki, ESMO Gastrointestinal Oncology, 8, 100153, https://doi.org/10.1016/j.esmogo.2025.100153

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrri, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A Vagionas, P Papakostas, A Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology 5, 100073

Exploring the use of a digital platform for cancer patients to report their demographics, disease and therapy characteristics, age, and educational disparities: An early-stage feasibility study, Galiti D., Linardou H., Agelaki S., Karampeazis A., Tsoukalas N., Psyrri A., Karamouzis M., Syrigos K.N., Ardavanis A., Athanasiadis I., Arvanitou E., Sgourou S., Mala A., Vallilas Ch., Boukovinas I. (2023). Current Oncology, 30(8), 7608-7619.

CureCancer platform facilitates patients’ self-data recording, treatment adherence and “distancing interventions”. A feasibility and satisfaction study, Galiti D., Linardou H., Agelaki S., Karampeazis A., Tsoukalas N., Psyrri A., Karamouzis M., Syrigos K., Ardavanis A., Athanasiadis I., Arvanitou E., Sgourou S., Kouloulias V., Mala A., Vallilas Ch., Boukovinas I. (2022). Clinics of Oncology, 6(3), 1-8.

Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). , Michael Liontos, Eleni Timotheadou, Emmanouil S Saloustros, Anna Koumarianou, Ilias Athanasiadis, Sofia Karageorgopoulou, Pavlos Papakotoulas, Ioannis Syrios, Georgios Kesisis, Christos Papadimitriou, Eirini Biziota, Maria Skondra, Stylianos Giassas, Eleftherios Kampletsas, Stavros Peroukidis, Christos Christodoulou, Fotini Papageorgiou, Ioannis Boukovinas, Zacharenia Saridaki, Journal of Clinical Oncology 40 (16_suppl), e18520-e18520

Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, ESMO open 6 (6), 100306 The first publication of the Hellenic Society of Medical Oncology (ΗeSMO) in the international journal ESMO Open.)

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254

The landscape of PIK3CA mutations and their prognostic impact on recurrence in HR+/HER2- breast cancer: A real-world multicenter analysis. Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025.Boutis A., Nikolaou M., Ardavanis A., Zagouri F., Koumarianou A., Timotheadou E., Tolis C., Christopoulou A., Korantzis I., Kampletsas E., Liontos M., Loga K., Kesisis G., Biziota I., Papatsimpas G., Karageorgopoulou S., Antoniadou K., Chatzifoti N., Saridaki Z. (2025).Presentation No. 219eP. ESMO Congress 2025, held in Berlin from 17–21 October 2025. The first publication of the Hellenic Society of Medical Oncology (ΗeSMO) in the international journal ESMO Open.)

Empowering Primary Care Providers (PCPs) in Cancer Survivorship: Insights from the ASCO | HeSMO Project ECHO in Greece. Tsoukalas N., Razis E., Boukovinas I., Lionis C., Chatzifoti N., Eaton V., Gould A., Kremzier M., Sarchet V., Schapira L., Saridaki Z. (2025). Presentation No. 3192eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025.

E1858P - fficacy and safety of thromboprophylaxis in oncology patients with Khorana score <2: Combined results from GMaT and ACT4CAT studies. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Kalofonos C., Psyrri A., Kapodistrias N., Papakostas P., Samantas E., Aravantinos G., Papakotoulas P., Boukovinas I. (2024), Annals of Oncology, 35(Suppl 2), p.S1094.

Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, Journal of Clinical Oncology 42 (16_suppl), 3146-3146

Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer. Pappas G., Tsoukalas N., Boutis A., Saloustros E., Gazouli I., Gkoura S., Zakopoulou R., Aidarinis C., Boukovinas I., Koumarianou A., Kokkali S., Gkoumas G., Vlachostergios P., Assi A., Karampeazis A., Nikolaidi A., Fountzila E., Chatzifoti N., Saridaki Z. (2024). Journal of Clinical Oncology, 42, Number 16_suppl.

439P - Testing HR+/HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Boutis A., Nikolaou M., Ardavanis A., Tolis C., Loga K., Korantzis I., Koumarianou A., Christopoulou A., Papatsimpas G., Bokas A., Pliarchopoulou K., Kampletsas E., Kesisis G., Biziota E., Psianou K., Karageorgopoulou S., Sogka E., Tsoukalas N., Chatzifoti N., Saridaki Z. (2023). Annals of Oncology, 34, S366.

2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Kalofonos C., Psyrri A., Kapodistrias N., Papakostas P., Pentheroudakis G., Aravantinos G., Papakotoulas P., Boukovinas I. (2023). Annals of Oncology, 34(Suppl 2), p.S1104.

Testing of newly diagnosed advanced high-grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Liontos M., Timotheadou E., Saloustros E.S., Koumarianou A., Athanasiadis I., Karageorgopoulou S., Papakotoulas P., Syrios I., Kesisis G., Papadimitriou C., Biziota E., Skondra M., Giassas S., Kampletsas E., Peroukidis S., Christodoulou C., Papageorgiou F., Boukovinas I., Saridaki Z. (2022). Journal of Clinical Oncology, 40, Number 16_suppl.

1585P - Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Nikolakopoulos A., Psyrri A., Kapodistrias N., Papakostas P., Aravantinos G., Athanasiadis A., Papakotoulas P., Boukovinas I. (2022). Annals of Oncology, 33(Suppl 7), p.S1270.

P-214 - Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study. Tsoukalas N., Christopoulou A., Anastopoulou G., Papandreou C., Timotheadou E., Athanasiadis I., Koumarianou A., Peroukidis S., Samelis G., Psyrri A., Kapodistrias N., Nikolakopoulos A., Andreadis C., Ardavanis A., Samantas E., Bokas A., Barbounis V., Kentepozidis N., Mavroudis D., Athanasiadis A., Papakotoulas P., Boukovinas I. (2021). Annals of Oncology, 32(Suppl 3), p.S172.

1692P - Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention? Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Athanasiadis I., Peroukidis S., Samelis G.F., Psyrri A., Kapodistrias N., Nikolakopoulos A., Demiri S., Andreadis C., Ardavanis A., Sgouros I., Bokas A., Barbounis V., Kentepozidis N., Mavroudis D., Papakotoulas P., Boukovinas I. (2021). Annals of Oncology, 32(Suppl 5), p.S1183.

Real-World Treatment Patterns and Outcomes for HR+/HER2- Metastatic Breast Cancer: Insights from a Greek Registry Study by the Hellenic Society of Medical Oncology. Boutis A., Agelaki S., Ardavanis A., Mavroudis D., Timotheadou E., Athanasiadis I., Kotteas E., Bobolaki I., Floros T., Karageorgopoulou S., Aravantinos G., Tsoukalas N., Samelis G., Tzovaras A., Dimitriadou A., Matsiakou F., Nikolaou M., Katsika L., Mala A., Chatzifoti N., Boukovinas I., Saridaki-Zoras Z. (2024) 7th Hellenic Congress of Oncology, Thessaloniki, April 24–27, 2024.

EA8: Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients: Combined results from the GMaT & ACT4CAT studies.
Tsoukalas N., Christopoulou A., Timotheadou E., Koumarianou A., Ardavanis A., Athanassiadis H., Bokas A., Peroukidis S., Koumakis G., Papatsimpas G., Samelis G., Psyrri A., Kapodistrias N., Nikolakopoulos A., Andreadis Ch., Papakostas P., Aravantinos G., Ziras N., Souggleri M., Kalofonos Ch., Kentepozidis N., Barbounis V., Samantas E., Makrantonakis P., Mala A., Pentheroudakis G., Demiri S., Tripodaki E.-S., Papandreou Ch., Mavroudis D., Anastopoulou G., Arvanitou E., Gkikas K., Papadopoulou P., Nikolaidis A., Kampoli A., Katsouli E., Dimitriadou A., Golfinopoulos S., Assi A., Mouzakiti A., Tzimu M., Perdikari Ch.-Ch., Giannakakou M., Litos I., Sofatzis I., Michas A., Binas I., Kostaridis E., Thalassinou P., Loulas N., Ardavanis-Loukeris G., Goumas G., Ioannou S., Karianakis G., Volakakis N., Pouliakis A., Athanassiadis A., Papakotoulas P., Boukovinas I. (2024).
7th Hellenic Congress of Oncology, Thessaloniki, April 24–27, 2024.

EA7: Electronic registry for recording the nutritional status and care of individuals with neoplastic disease – Dietary Assessment Recording of Oncology Patients (DROP).
Tsigkas A., Gioulbasanis I., Vidra N., Logothetis M., Giannakoulia M., Dimitrakopoulos G., Tsoukalas N., Kontogianni M. (2024).
7th Hellenic Congress of Oncology, Thessaloniki, April 24–27, 2024.

EA14: Real-world clinical practice data on thromboprophylaxis in patients with active cancer: A pooled analysis of the GMaT and ACT4CAT studies.
Tsoukalas N., Christopoulou A., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis H., Bokas A., Peroukidis S., Koumakis G., Papatsimpas G., Samelis G., Psyrris A., Kapodistrias N., Nikolakopoulos A., Andreadis C., Papakostas P., Aravantinos G., Ziras N., Souggleri M., Kalofonos H., Kentepozidis N., Barbounis V., Samantas E., Makrantonakis P., Mala A., Pentheroudakis G., Demiri S., Tripodaki E.-S., Papandreou H., Mavroudis D., Anastopoulou G., Arvanitou E., Gikas K., Papadopoulou P., Nikolaidis A., Kampoli A., Katsouli E., Dimitriadou A., Golfonopoulos S., Assi A., Mouzakiti A., Tzimu M., Perdikari K.-Ch., Giannakakou M., Litos I., Sofatzis I., Michas A., Binas I., Kostaridis E., Thalassinou P., Loulis N., Ardavanis-Loukeris G., Goumas G., Ioannou S., Karianakis G., Volakakis N., Pouliakis A., Athanasiadis A., Papakotoulas P., Boukovinas I. (2023).
29th Hellenic Congress of Clinical Oncology, Athens, April 5–8, 2023.

EA12: Assessment of newly diagnosed patients with advanced high-grade ovarian cancer (OC) using the Myriad Genetics MyChoice CDx PLUS diagnostic test highlights the need for public insurance coverage of genetic testing: Results from a national ΗESMO program.
Liontos M., Timotheadou E., Saloustros Em., Koumarianou A., Athanasiadis H., Karageorgopoulou S., Papakotoulas P., Syrios I., Kesisis G., Papadimitriou Ch., Biziota E., Skondra M., Giassas S., Kampletsas E., Peroukidis S., Christodoulou Ch., Kantzioura A., Nikolaou M., Papaxoïnis G., Soupos N., Fotarelli A., Emmanouilidis Ch., Kotsakis A., Mavroudis D., Bokas A., Stamatopoulou S., Tolis Ch., Mauri D., Anagnostopoulos A., Georgoulias V., Korantzis I., Koutras A., Koutsoukos K., Papadopoulos G., Papanikolaou S., Pouptsis A., Romanidou O., Touroutoglou N., Tsiara A., Floros Th., Agorastos A., Adamidis A., Andreadis Ch., Andreadou A., Gouberis P., Demiri S., Dimoudis S., Kalykaki A., Kanaloupiti D., Kapodistrias N., Makatsoris Th., Mountzios I., Botsolis K., Nasi D., Douvelis E., Xanthakis I., Oikonomopoulou P., Papazisis K., Perdikouri E.I., Pispirigou M., Ploiarchopoulou K., Razi E., Rallis G., Rapti K., Stamati D., Stefanou D., Tzanninis D., Tryfonopoulos D., Fassas A., Fountzila E., Charalambakis N., Hatsidis G., Christopoulou A., Aravantinos G., Ardavanis A., Efthymiadis K., Zagouri F., Zakopoulou R., Zarkavelis G., Zafeiriou Z., Ziogas D., Zlatintsi S., Thomopoulou K., Kalofonos H., Kaltsas S., Karanikiotis Ch., Katopodi O., Kosmas H., Kosmidis P., Kourousis Ch., Kostadima L., Lampropoulos S., Laschos K., Levva S., Lianos E., Makrantonakis P., Maragos Ch., Mitsimponas N., Michalaki B., Barbounis V., Bafaloukos D., Boutis A., Neanidis K., Nikiforidis L., Nikolakopoulos A., Ntoufexis D., Oikonomopoulos G., Orfanos G., Panou M., Papanastassopoulos P., Papafili A., Paraskeva M., Pektasidi E., Petrakis D., Pouptsis A., Rigakos G., Rigas G., Spathas N., Sfika A., Tegos Th., Tzovaras A., Tripodaki E.S., Tsoukalas N., Papageorgiou F., Boukovinas I., Saridaki Z. (2022).
6th Hellenic Congress of Oncology, Thessaloniki, May 4–7, 2022.

AA7: Prevention of venous thromboembolism in ambulatory patients with active cancer: Results from the ACT4CAT study.
Tsoukalas N., Christopoulou A., Koumarianou A., Timotheadou E., Athanasiadis H., Samelis G., Peroukidis S., Psyrris A., Kapodistrias N., Nikolakopoulos A., Demiri S., Andreadis Ch., Bokas A., Tripodaki E.-S., Ardavanis A., Samantas E., Papandreou H., Kalofonos H., Mavroudis D., Kentepozidis N., Barbounis V., Anastopoulou G., Arvanitou E., Gikas K., Papadopoulou P., Nikolaidis A., Kampoli A., Katsouli E., Dimitriadou A., Golfonopoulos S., Assi A., Mouzakiti A., Tzimu M., Perdikari K.-Ch., Giannakakou M., Litos I., Sofatzis I., Mala A., Michas A., Binas I., Thalassinou P., Loulis N., Ardavanis-Loukeris G., Volakakis N., Athanasiadis A., Papakotoulas P., Boukovinas I. (2022). 6th Hellenic Congress of Oncology, Thessaloniki, May 4–7, 2022.

Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report, Zacharenia Saridaki, Elena Fountzilas, Athanasios Alexopoulos, Niki Karachaliou, BMC Medical Genomics, Volume 18, article number 51, (2025)

Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns, Elena Fountzilas, Theofanis Papadopoulos, Eirini Papadopoulou, Cedric Gouedard, Helen P Kourea, Pantelis Constantoulakis, Christina Magkou, Maria Sfakianaki, Vassiliki Kotoula, Dimitra Bantouna, Georgia Raptou, Angelica A Saetta, Georgia Christopoulou, Dimitris Hatzibougias, Electra Michalopoulou-Manoloutsiou, Eleni Siatra, Eleftherios Eleftheriadis, Evangelia Kavoura, Loukas Kaklamanis, Antigoni Sourla, George Papaxoinis, Kitty Pavlakis, Prodromos Hytiroglou, Christina Vourlakou, Petroula Arapantoni-Dadioti, Samuel Murray, George Nasioulas, Grigorios Timologos, George Fountzilas, Zacharenia Saridaki, Diagnostics 14 (11), 1076

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer, Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsaousis, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, Florentia Fostira, George Fountzilas, Michalis Liontos, Cancers 15(23), 5525

Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, ESMO open 6 (6), 100306

Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVer study): a prospective cohort study of the Hellenic Cooperative Oncology Group, Helena Linardou, Nikolaos Spanakis, Georgia-Angeliki Koliou, Athina Christopoulou, Sofia Karageorgopoulou, Nephely Alevra, Anastasios Vagionas, Nikolaos Tsoukalas, Stavroula Sgourou, Elena Fountzilas, Joseph Sgouros, Evangelia Razis, Dimitra Chatzokou, Sofia Lampaki, Zacharenia Saridaki, Giannis Mountzios, George Saroglou, George Fountzilas, Cancers 13 (18), 4621

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254

Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma, Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrri, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis,

George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou, Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas, Philippos C Patsalis, Cancers 13 (2), 198

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group,Elena Fountzilas, Georgia-Angeliki Koliou, Athanassios Vozikis, Vassiliki Rapti, Achilleas Nikolakopoulos, Anastasios Boutis, Athina Christopoulou, Ioannis Kontogiorgos, Sofia Karageorgopoulou, Efthalia Lalla, Dimitrios Tryfonopoulos, Ioannis Boukovinas, Cleopatra Rapti, Adamantia Nikolaidi, Sofia Karteri, Evangelia Moirogiorgou, Ioannis Binas, Davide Mauri, Gerasimos Aravantinos, Flora Zagouri, Zacharenia Saridaki, Amanda Psyrri, Dimitrios Bafaloukos, Anna Koumarianou, Helena Linardou, Giannis Mountzios, Evangelia Razis, George Fountzilas, Georgios Koumakis, ESMO open 5 (4), e000774

PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer, M Sfakianaki, C Papadaki, M Tzardi, M Trypaki, S Manolakou, I Messaritakis, Z Saridaki, D Mavroudis, V Georgoulias, J Souglakos, Annals of Oncology 30, iv21-iv22

Association of notch and hedgehog pathway activation with prognosis in early-stage colorectal cancer, Grigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, Kyriaki Manousou, Georgia-Angeliki Koliou, Ioannis Kostopoulos, Vassiliki Kotoula, Thomas Makatsoris, Helen P Kourea, Georgia Raptou, Sofia Chrisafi, Epaminontas Samantas, Kleo Papaparaskeva, Elissavet Pazarli, Pavlos Papakostas, Georgia Kafiri, Davide Mauri, Alexandra Papoudou-Bai, Christos Christodoulou, Kalliopi Petraki, Nikolaos Dombros, Dimitrios Pectasides, George Fountzilas, Anticancer Research 39 (4), 2129-2138

Colchicum genus in the writings of ancient Greek and Byzantine physicians, Gregory Tsoucalas, Theodoros Papaioannou, George Panayiotakopoulos, Zenia Saridaki, Dimitrios A Vrachatis, Marianna Karamanou, Current pharmaceutical design 24 (6), 648-653

Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy, S Pontikakis, C Papadaki, M Tzardi, M Trypaki, M Sfakianaki, F Koinis, E Lagoudaki, L Giannikaki, A Kalykaki, E Kontopodis, Z Saridaki, N Malamos, V Georgoulias, J Souglakos, The pharmacogenomics journal 17 (6), 506-514

Reduced expression of SMAD4 is associated with poor survival in colon cancer, Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas Alexander McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fredrik T Bosman, Roberto Fiocca, Clinical Cancer Research 22 (12), 3037-3047

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma, Zacharenia Saridaki, Georgia Lambrodimou, Stefanos Kachris, Paris Makrantonakis, Ioannis Boukovinas, Aris Polyzos, Athanasios Anagnostopoulos, Athanasios Athanasiadis, Dimitris Stoltidis, Vassilis Georgoulias, John Souglakos, American Journal of Clinical Oncology 38 (1), 17-22

Avenzoar’s (1091-1162) clinical description of cancer, M Karamanou, G Tsoucalas, Z Saridaki, C Iavazzo, G Androutsos, J BUON 20 (4), 1171-4

René-Théophile-Hyacinthe Laennec (1781-1826) and the description of metastatic pulmonary melanoma, M Karamanou, AJ Stratigos, Z Saridaki, G Tsoucalas, G Androutsos, J BUON 20 (1), 354-6

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?, Z Saridaki, X Saegart, Veerle De Vriendt, D Hatzidaki, Sander Palmans, Linde De Smedt, Gert De Hertogh, Sabine Tejpar, British Journal of Cancer 113 (6), 914-920

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, D Klingbiel, Z Saridaki, AD Roth, FT Bosman, M Delorenzi, Sabine Tejpar, Annals of oncology 26(1), 126-132

Cost-effectiveness analysis of panitumumab+ mFOLFOX over bevacizumab+ mFOLFOX as a first-line treatment for metastatic colorectal cancer patients with wild-type RAS in Greece, G Kourlaba, I Boukovinas, Z Saridaki, V Papagiannopoulou, G Tritaki, N Maniadakis, Value in Health 17 (7), A633

ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samplesExpressão ERCC1 Correlacionada com EGFR e VariáRevista Portuguesa de Pneumologia (English Edition) 20 (4), 200-207veis Clinicopatológicas em Doentes com Carcinoma Pulmonar de Não Pequenas Células. Um estudo imunocitoquímico em amostras biópsias aspirativas por agulha fina, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, Z Saridaki, M Tzardi, Revista Portuguesa de Pneumologia (English Edition) 20(4), 200-207

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy, Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar, Clinical Cancer Research 20 (17), 4499-4510

Prognostic and predictive significance of MSI in stages II/III colon cancer, Z Saridaki, J Souglakos, V Georgoulias, Z Saridaki, J Souglakos, V Georgoulias, World Journal of Gastroenterology: WJG 20 (22), 6809

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Its Impact on Patients’ Outcome, Zacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, Chara Papadaki, Alexandra Voutsina, Aristea Kalykaki, Ippokratis Messaritakis, Kyriakos Mpananis, Dimitris Mavroudis, Efstathios Stathopoulos, Vassilis Georgoulias, John Souglakos, PloS one 8 (12), e84604

The eminent dermatologist Moriz Kaposi (1837-1902) and the first description of idiopathic multiple pigmented sarcoma of the skin, M Karamanou, C Antoniou, AJ Stratigos, Z Saridaki, G Androutsos, J buon 18 (4), 1101-5

The great surgeon Jean-Louis Faure (1863-1944) and his contribution in the treatment of uterine cancer, M Karamanou, Z Saridaki, M Piagkou, K Laios, G Androutsos, J BUON 18 (1), 296-298

Aretaeus of Cappadocia and the first description of diabetes, K Laios, M Karamanou, Z Saridaki, G Androutsos, Hormones 11, 109-113 A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5- fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial, Z Saridaki, N Androulakis, N Vardakis, L Vamvakas, E Kabouraki, K Kalbakis, D Hatzidaki, A Voutsina, D Mavroudis, V Georgoulias, J Souglakos, British journal of cancer 107 (12), 1932-1937

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer, Zacharenia Saridaki, Nikolaos Malamos, Panagiotis Kourakos, Aristides Polyzos, Alexandros Ardavanis, Nikolaos Androulakis, Kostas Kalbakis, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 69, 35- 42

Cytopathologic interpretation of ascites due to malignancy, A Kalogeraki, I Karvela- Kalogeraki, D Tamiolakis, P Petraki, A Papathanasiou, Z Saridaki, EN Stathopoulos, M Tzardi, J buon 17 (3), 446-51

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients, Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristea Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efstathios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos, PloS one 6 (1), e15980

Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle, S Tejpar, Z Saridaki, M Delorenzi, F Bosman, AD Roth, Journal of the National Cancer Institute 103 (11), 841-844

Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer, Nikolaos Vardakis, Ippokratis Messaritakis, Chara Papadaki, Georgios Agoglossakis, Maria Sfakianak i, Zacharenia Saridaki, Stella Apostolaki, Ioannis Koutroubakis, Maria Perraki, Dora Hatzidaki, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos, Clinical Cancer Research 17 (1), 165-173

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer, E Saloustros, K Kalbakis, N Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulias, D Mavroudis, J BUON 16 (2), 215-8

Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study, Athanasios G Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvakas, Nikolaos Vardakis, Zacharenia Saridaki, George Samonis, Stylianos Giassas, Vassilis Georgoulias, Sophia Agelaki, Clinical Lung Cancer 12 (2), 100-105

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer, Panayiotis A Theodoropoulos, Hara Polioudaki, Sofia Agelaki, Galatea Kallergi, Zacharenia Saridaki, Dimitris Mavroudis, Vassilis Georgoulias, Cancer letters 288 (1), 99-106

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome, Z Saridaki, D Papadatos-Pastos, M Tzardi, D Mavroudis, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulias, J Souglakos, British journal of cancer 102 (12), 1762-1768

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer, Zacharenia Saridaki, Vassilis Georgoulias, John Souglakos, World journal of gastroenterology: WJG 16 (10), 1177

A retrospective analysis of non-platinum-based first-and second-line chemotherapy in patients with advanced non-small cell lung cancer, Athanasios Kotsakis, Dora Hatzidaki, Lambros Vamvakas, Nikolaos Vardakis, Antonia Kalykaki, Vasiliki Bozionelou, Nikolaos Androulakis, Kostas Kalbakis, Zacharenia Saridaki, Vassilis Georgoulias, Sophia Agelaki, Anticancer research 30 (10), 4335-4342

Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study, Charalambos Kouroussis, Lambros Vamvakas, Nikolaos Vardakis, Athanasios Kotsakis, Antonia Kalykaki, Kostas Kalbakis, Zacharenia Saridaki, Nikolaos Kentepozidis, Stelios Giassas, Vassilis Georgoulias, Oncology 76 (2), 112-117

A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors, Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Marios Marselos, Vassilis Georgoulias, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 65, 121-128

Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy, Z Saridaki, M Tzardi, D Papadatos-Patsos, E Kampouraki, E Zois, E Stathopoulos, V Georgoulias, D Mavroudis, J Souglakos, EJC Supplements 2 (7), 91-92

Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial, Ioannis Gioulbasanis, Zacharenia Saridaki, Antonia Kalykaki, Lambros Vamvakas, Kostas Kalbakis, Michail Ignatiadis, Kyriakos Amarantidis, Stylianos Kakolyris, Vassilis Georgoulias, Dimitris Mavroudis, Anticancer research 28 (5B), 3019-3025

A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors, Zacharenia Saridaki, Vasiliki Bozionelou, Nikolaos Kentepozidis, Athanasios Kotsakis, Nikolaos Vardakis, Antonia Kalykaki, Ioannis Gioulbasanis, Athanasios Karampeazis, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis, Oncology 72 (1-2), 45-50

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract, I Gkioulbasanis, J Souglakos, N Vardakis, A Kotsakis, Z Saridaki, N Kentepozidis, A Polyzos, S Giassas, Michail Ignatiadis, V Bozionelou, C Christophylakis, Vassilis Georgoulias, JOURNAL-BALKAN UNION OF ONCOLOGY 12 (2), 197

A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors, A Kalykaki, L Vamvakas, Sofia Agelaki, K Kalbakis, N Vardakis, G Sfakiotaki, Michail Ignatiadis, Z Saridaki, A Karampeazis, D Mavroudis, V Georgoulias, Oncology 71 (3- 4), 197-203 10 2007

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status, John Souglakos, Lambros Vamvakas, Stella Apostolaki, Maria Perraki, Zacharenia Saridaki, Irine Kazakou, Athanasios Pallis, Charalambos Kouroussis, Nikos Androulakis, Kostas Kalbakis, Georgia Millaki, Dimitris Mavroudis, Vassilis Georgoulias, Breast Cancer Research 8 (4), 1-8

Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors, Ch Kouroussis, N Androulakis, L Vamvakas, A Kalykaki, S Spiridonakou, N Kentepozidis, Z Saridaki, El Xiropoulou, V Georgoulias, Oncology 69 (3), 202-207

Idiopathic CD4+ T lymphocytopenia disclosed by recurrent cryptococcal meningitis. First case report from Greece, Diamantis P Kofteridis, Zacharenia Saridaki, Ireni Kazakou, Silvia Lazaridou, Dimitris Alegakis, Georgia Milaki, Achilleas Gikas, International Journal of Infectious Diseases 9 (6), 347-348

A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors, John Souglakos, Stylianos Kakolyris, Nikolaos Vardakis, Nikolaos Androulakis, Dimitrios Mavroudis, Lambos Vamvakas, Charalambos Kouroussis, Sophia Agelaki, Zacharenia Saridaki, Vassilis Georgoulias, Cancer investigation 23 (6), 505- 510

Endothelial p21WAF1/Cip1 cell cycle inhibitor is down-regulated in breast cancer, T Vrekoussis, EN Stathopoulos, M Kafousi, Z Saridaki, E Sanidas, O Zoras, Anticancer research 25 (4), 2743-2748

Intestinal ischemia as the first manifestation of vasculitis, Freda H Passam, Ioannis D Diamantis, Garyfalia Perisinaki, Zenia Saridaki, Herakles Kritikos, Dimitrios Georgopoulos, Dimitrios T Boumpas, Seminars in arthritis and rheumatism 34 (1), 431-441

Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, O Zoras, DA Spandidos, British Journal of Dermatology 148 (4), 638-648

First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer, G Fiorentini, D Tsetis, P Bernardeschi, C Varveris, S Rossi, A Kalogeraki, E Athanasakis, P Dentico, P Kanellos, M Biancalani, S Almarashdah, G Zacharioudakis, Z Saridaki, G Chalkiadakis, E Xynos, O Zoras, Anticancer research 23 (5), 4339-4346

Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction, DP Kofteridis, S Karabekios, JG Panagiotides, J Bizakis, D Kyrmizakis, Z Saridaki, A Gikas, Journal of chemotherapy 15 (3), 282-286

Surgical repair of incisional ventral hernias: tension-free technique using prosthetic materials (expanded polytetrafluoroethylene Gore-Tex Dual Mesh), Emmanuel Chrysos, Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Dimitra Dimitriadou, Vasilios Koutsoumpas, George Chalkiadakis, Evangelos Xynos, Odysseas Zoras, The American Surgeon 66 (7), 679-682

High frequency of loss of heterozygosity on chromosome region 9p21–p22 but lack of p16INK4a/p19ARF mutations in Greek patients with basal cell carcinoma of the skin, Zacharenia Saridaki, George Sourvinos, Demetrios A Spandidos, Elma Koumantaki, Triantafillos Liloglou, Othon Papadopoulos, Odysseas Zoras, Journal of investigative dermatology 115 (4), 719-725

Surgical repair of inguinal hernia: tension free technique with prosthetic materials (Gore- Tex Mycro Mesh expanded polytetrafluoroethylene), Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Emmanuel Chrysos, George Prokopakis, Nickolaos Vrahasotakis, Evangelos Xynos, George Chalkiadakis, Odysseas Zoras, The American Surgeon 66 (8), 728- 731